Investing in biotech stocks isn't for everyone because the very nature of their business is fraught with risk. As a result, ...

Vertex Pharmaceuticals Incorporated looks set for two new drug approvals in early 2025. Click here to read an analysis of ...

In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report). The company’s ...

Jefferies has upgraded Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), citing the company’s robust cystic fibrosis base business ...

Most sickle cell disease patients who received the gene-editing therapy Casgevy have been free from vaso-occlusive crises for ...

In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $469.29, indicating a -0.99% shift from the previous trading day.

The stock's fall snapped a two-day winning streak.

Vertex Pharmaceuticals (VRTX) announced longer-term data for CASGEVY from global clinical trials in people with severe sickle ...

Saudi Arabia’s Ministry of Industry and Mineral Resources signed a memorandum of understanding (MoU) with US-based Vertex ...

US biopharma Vertex Pharmaceuticals has previously presented positive Phase III data on suzetrigine, an investigational, oral ...

Vertex Pharmaceuticals (VRTX) presented positive long-term data for its gene therapy Casgevy and issued a business update on ...

Two Saudi Arabian agencies signed on with Vertex Pharmaceuticals to help boost the countr | The Vertex agreement is part of ...